Business Wire

FLIR Receives Additional $26M Contract for U.S. Army’s Nuclear, Biological and Chemical Reconnaissance Vehicle Program

15.10.2020 17:02:00 EEST | Business Wire | Press release

Share

FLIR Systems, Inc. (NASDAQ: FLIR) announced it has been awarded a $26 million contract modification in support of the Nuclear, Biological and Chemical Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU) program for the U.S. Army. The Other Transaction Authority (OTA) agreement was awarded through the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) as a follow-on to a $48 million contract announced in April 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005675/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FLIR is lead integrator in modernizing the U.S. Army’s Nuclear, Biological and Chemical Reconnaissance Vehicle (NBCRV) system with improved and autonomous CBRN sensors. Earlier this year, soldiers at Fort Bliss, Texas employed a FLIR prototype in realistic battlefield scenarios to sense and rapidly avoid CBRN hazards. The new contract allows FLIR to continue developing the Sensor Suite and also will pair the NBCRV with a ground robotic vehicle to expand the system’s use with manned-unmanned teams. (Photo: Business Wire)

FLIR is the lead integrator in modernizing the Army’s NBCRV system with improved and autonomous CBRN sensors. Earlier this year, the company delivered initial prototypes of the NBCRV SSU system for a focused assessment at Fort Bliss, Texas. Soldiers employed the FLIR prototype in realistic battlefield scenarios to sense and rapidly avoid CBRN hazards. The new contract allows FLIR to continue developing the Sensor Suite and to deliver mature prototypes for government testing in 2021.

Among other third-party solutions, the NBCRV Sensor Suite will feature capabilities of the FLIR R80D SkyRaider™ drone integrated with a specialized version of the FLIR IBAC bio-detection sensor. This next phase also will pair the NBCRV with a ground robotic vehicle to expand the system’s use with manned-unmanned teams. A FLIR-developed command and control system will bring together all devices and platforms with sensor fusion and automation features that lessen the cognitive burden on users and improve decision-making.

“Our ability to build and integrate manned and unmanned sensing solutions across a wide threat space is where FLIR differentiates itself,” said Vice President and General Manager of the Unmanned Systems & Integrated Solutions business at FLIR, Roger Wells. “Incorporating UAV and UGV platforms into NBCRV aligns with our efforts to develop full sensing capabilities that can act as force multipliers and boost mission success for our troops.

“Whether through air- or ground-based detection systems, FLIR is uniquely positioned in the defense industry with deep expertise in both intelligent sensor and autonomous systems technology that keeps warfighters safe,” Wells added.

FLIR is supporting other efforts by JPEO-CBRND. In the past year, the company has won two contracts worth more than $55 million to field its FLIR Agentase™ C2 chemical warfare disclosure spray, formulated to detect nerve agents like VX and sarin as well as blister agents such as sulfur mustard.

Work on the NBCRV program has begun and is expected to continue through 2022 at FLIR facilities in West Lafayette, Indiana; Stillwater, Oklahoma; and Elkridge, Maryland. For more on FLIR System’s integrated solutions for government and defense, visit www.flir.com/integrated-solutions. For more on FLIR’s chemical, biological, radiological, nuclear, and explosive detection technologies, visit www.flir.com/threat-detection.

About FLIR Systems, Inc.

Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense,” creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.

Forward Looking Statements

The statements in this release by Roger Wells and the other statements in this release about the contract and order described above are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates, and projections about FLIR's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including the following: the ability to manufacture and deliver the systems referenced in this release, changes in pricing of FLIR's products, changing demand for FLIR's products, product mix, the impact of competitive products and pricing, constraints on supplies of critical components, excess or shortage of production capacity, the ability of FLIR to manufacture and ship products in a timely manner, FLIR's continuing compliance with U.S. export control laws and regulations, and other risks discussed from time to time in FLIR's Securities and Exchange Commission filings and reports. In addition, such statements could be affected by general industry and market conditions and growth rates, and general domestic and international economic conditions. Such forward-looking statements speak only as of the date on which they are made and FLIR does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release, or for changes made to this document by wire services or Internet service providers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Joe Ailinger, Jr.
FLIR Systems
Phone: +1 781-801-6161
Email: joe.ailinger@flir.com

Investor Relations:
Lasse Glassen
Addo Investor Relations
Phone: 424-238-6249
Email: lglassen@addoir.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye